Sight Sciences Inc (SGHT) financials

NASDAQ · Health Care

$9.32 -2.61% Close Oct 30, 2026 Live

Sight Sciences revenue and earnings by year

Sight Sciences's revenue was $77.4 million in the fiscal year to December 31, 2025, down 3.1% from the year before. Net income was -$38.4 million, -49.7% of revenue. Since the fiscal year to December 31, 2018, revenue has grown 39.5% a year on average.

RevenueNet income
-$50.0M$0$50.0M
20182019202020212022202320242025

Fiscal years, each labelled by the calendar year it ended in.

Income statement, the last 8 fiscal years

In millions of US dollars except per-share figures. Each column is a fiscal year, named by the month it ended.
Fiscal year toDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
Revenue778081714928238
Revenue growth-3.1%-1.5%13.6%45.7%77.1%18.4%210.1%—
Gross profit676869594018175
Gross margin86.2%85.5%85.3%82.7%82.4%66.7%72.0%69.0%
Operating income-37-51-57-84-51-32-24-14
Operating margin-48.0%-63.3%-70.7%-117.7%-105.2%-116.5%-103.0%-189.9%
Net income-38-52-56-86-63-35-26-14
Net margin-49.7%-64.5%-68.5%-120.9%-128.6%-125.5%-110.8%-189.8%
Diluted EPS-$0.74-$1.03-$1.14-$1.80—-$3.71——
Free cash flow-30-23-48-77-53-33-26-15

Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open SGHT in Markets.

How Sight Sciences makes money

Revenue by segment in the quarter to June 30, 2026, as the company reports it.

SegmentRevenueShare
Surgical Glaucoma$20.7M88.6%
Dry Eye$2.67M11.4%

See also: SGHT returns

No forecast, no recommendation. This page describes Sight Sciences Inc from published data; it is not advice to buy, sell or hold any security.

Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.